Skip to main content
MEMPHASYS LIMITED. logo

MEMPHASYS LIMITED. — Investor Relations & Filings

Ticker · MEM ISIN · AU000000MEM5 LEI · 549300RZ3LBXHF3WXL97 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,221 across all filing types
Latest filing 2009-06-11 Capital/Financing Update
Country AU Australia
Listing ASX MEM

About MEMPHASYS LIMITED.

https://www.memphasys.com/

Memphasys Limited is a biotechnology company specializing in the development of advanced cell separation and reproductive biotechnology solutions. The company's core technology platform utilizes proprietary membranes and electrophoresis to isolate high-quality cells from biological fluids. Its flagship product, the Felix™ system, is an automated device designed for the rapid separation of high-quality sperm from semen samples for use in human assisted reproductive technology (ART) procedures. This technology aims to improve clinical outcomes by selecting sperm with lower DNA fragmentation and higher motility compared to traditional centrifuge-based techniques. Beyond human fertility, the company applies its bio-separation expertise to animal health, including diagnostic tools for stallion fertility. Memphasys focuses on providing innovative solutions that enhance efficiency and success rates in the global reproductive health market.

Recent filings

Filing Released Lang Actions
NSP Extension of Prospectus Closing Date 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the extension of the prospectus closing date and a company name change from NuSep to NxGen Pharmaceuticals. It provides background information about the company, its products, and market positioning. There is no detailed financial data, no regulatory filing forms, no financial statements, and no mention of an annual or quarterly report. The document is an announcement related to capital raising activities (prospectus closing date extension) and corporate identity change, which fits best under Capital/Financing Update (CAP). The length is about 4937 characters, which is consistent with a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2009-06-11 English
NxGen Newsletter 4 pages ?Kb
Investor Presentation Classification · 85% confidence The document is a newsletter-style update from NxGen dated June 2009, describing business expansion plans, clinical trials, and current projects. It includes detailed descriptions of ongoing R&D activities, clinical trial phases, and market strategies. There is no indication that this is an official regulatory filing, annual or interim financial report, earnings release, or any formal corporate announcement such as a proxy statement or voting results. The content is informational and promotional about business developments and product innovations, typical of an investor or corporate update presentation. Given the detailed business and strategic information aimed at investors and stakeholders, this fits best as an Investor Presentation (IP). The document length (6505 characters) and content support this classification rather than a brief announcement or regulatory filing.
2009-06-04 English
NuSep Results of EGM 3 pages ?Kb
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the results of an Extraordinary General Meeting (EGM) held on 2 June 2009 by NuSep Ltd. It includes voting results on various resolutions such as return of capital, grant of options, and election of a director. The document also provides background information about the company and its products, as well as information about the company's name change and ASX code change. There are no financial statements or detailed financial performance data presented, nor is this a transcript of a call or a report publication announcement. The primary content is the official results of shareholder votes at a general meeting, which fits the definition of "Declaration of Voting Results & Voting Rights Announcements (DVA)".
2009-06-01 English
Disclosure Document 1 page ?Kb
Regulatory Filings
2009-05-28 English
Extension of Prospectus Closing Date / Administration Update 4 pages ?Kb
Regulatory Filings
2009-05-28 English
NxGen Commences US Expansion 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a press release announcing NxGen's commencement of US expansion, including signing a heads of agreement for a US manufacturing and marketing facility. It references a prospectus dated 7 May 2009 for full details and provides background on the company and its products. The document is an announcement of business development and strategic plans rather than a financial report or regulatory filing. It does not contain financial statements, audit information, voting results, or executive changes. It is not a report itself but an announcement of a corporate development. Therefore, the most appropriate classification is a Regulatory Filing (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2009-05-25 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.